Inhibition of experimental angiogenesis of cornea by somatostatin

Wu, Ping; Liu, Chi Chang; Chen, Chih Hsin; Kou, H.; Shen, Su‐Chin; Liu, Cheng; Chou, Wen-Ying; Sung, Ming Tse; Yang, Lin

doi:10.1007/s00417-002-0591-7

Cited by 39 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 Recent studies have shown that angiogenesis inhibitors, such as endostatin, angiostatin, somatostatin, tissue inhibitor of metalloproteinase-3, peptide derived from thrombospondin-1, prolactin and brain-specific angiogenesis inhibitor 1 (BAI1), can inhibit corneal neovascularization and maintain corneal avascularity. [9][10][11][12][13][14][15][16] GA-binding protein (GABP) is a ubiquitously expressed nuclear transcription factor that is involved in a broad range of cellular processes and that regulates target gene expression in the cell cycle and cellular metabolism. 17 GABP is composed of two subunits: GABPa contains the erythroblast transformation-specific DNA-binding domain, whereas the substitutable subunit, GABPb or GABPg, contains ankyrin repeats and the transcriptional activation domain.…”

Section: Introductionmentioning

confidence: 99%

Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model

et al. 2009

View full text Add to dashboard Cite

Corneal neovascularization can reduce visual acuity. GAbinding protein (GABP) is a transcription factor that regulates the expression of target genes including vascular endothelial growth factor (VEGF) and roundabout4 (Robo4), which participate in pathologic angiogenesis. We assessed whether intraocular injection of the GABP gene affects the growth of new corneal blood vessels in a mouse ocular neovascularization model. Transfection of human GABPa and GABPb gene (GABPa/b) into human conjunctival epithelial cells resulted in decreased VEGF and Robo4 expression. Three groups of mice underwent chemical and mechanical denudation of the corneal epithelium. Subsequently, two groups were administered subconjunctival injection of lipoplexes carrying plasmid DNA encoding for human GABPa/b or an empty plasmid DNA at 1-week intervals. The third group served as an experimental control. In vivo delivery of human GABPa/b into mouse neovascularized cornea reduced VEGF and Robo4 gene expression. Biomicroscopic examination showed that, at 1 week after one or two injections, GABPa/b-treated eyes had significantly less neovascularized corneal area than did eyes treated with the empty vector. Histologic examination showed significantly less vascularized area and fewer blood vessels in the GABP-treated group at 1 week after injections. However, these angiosuppressive effects were weakened at 2 weeks after injections. Our results indicate that subconjunctival GABP gene delivery delays corneal neovascularization for up to 2 weeks in a mouse model of deliberate corneal injury.

show abstract

Section: Introductionmentioning

confidence: 99%

Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model

et al. 2009

View full text Add to dashboard Cite

show abstract

“…These include medication, laser photocoagulation, and surgery. Several angiogenesis inhibitors have been identified and tried as medical treatment, including prolactin, 3 endostatin, 7 angiostatin, 8 somatostatin, 9 cyclosporin A, 18 TNP-470, 19 steroids, 20 nonsteroidal antiinflammatory drugs, 21 thalidomide, 22 methotrexate, 23 and culture supernatant of human amniotic cells. 24 Recently, targeted macrophage metalloelastase or angiostatin gene transfer has been tried to halt angiogenesis in a mouse tumor model, 25,26 and naked plasmids have been shown to be taken up by corneal epithelium.…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5] Recognition of the potential benefits of controlling angiogenesis has led to a search for angiogenesis inhibitors. 6 Several angiogenesis inhibitors have been identified, such as prolactin, 3 endostatin, 7 angiostatin, 8 somatostatin, 9 and peptide derived from thrombospondin-1 (TSP1), 10 although some of which are the fragments of larger proteins. However, there have been a few studies of gene delivery as a way to reduce neovascularization in the eye.…”

Section: Introductionmentioning

confidence: 99%

Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model

et al. 2005

Gene Ther

View full text Add to dashboard Cite

Corneal neovascularization, which occurs in many pathologic states of the cornea, reduces the visual acuity. Recently, we found that the extracellular region of brain-specific angiogenesis inhibitor 1 (BAI1-ECR) has antiproliferative activity through functional blocking of a v b 5 integrin in endothelial cells. In this study, we investigated the effects of lipidmediated subconjunctival injection of the BAI1-ECR gene on corneal angiogenesis induced by epithelial debridement by heptanol in the rabbit. When a pEGFP-BAI1-ECR plasmid was given subconjunctivally 1 week after epithelial debridement, green fluorescence was detected in the corneal stroma with expression persisting for 7 days. To test the effect of BAI1-ECR on neovascularization, rabbits were injected with the BAI1-ECR gene or empty vector two or three times at 1-week intervals beginning 1 week after debridement. When measured with biomicroscopy at 1 or 2 weeks after two weekly injections, BAI1-delivered eyes had significantly less neovascularized corneal area than vector-injected ones in both time periods. Similar microscopic results were obtained after three weekly injections of BAI1-ECR. In quantitative histological examination, the BAI1-receiving eyes showed significantly less neovascular area and number of vessels than vector-injected ones. Also, after two weekly injections, BAI1-delivered eyes had decreased neovascularized corneal area equivalent to that of anti-VEGF antibody-injected ones. These results indicate that BAI1-ECR gene delivery effectively reduces experimental corneal neovascularization and suggest that the BAI1-ECR protein can be used as an angiogenesis suppressor in the eye. Gene Therapy (2005) 12, 617-624.

show abstract

“…Despite the recent progress in the graphic editing software, automated methods have some limitations. First, the optimization and validation of any automated quantitative tool are questionable [36][37][38]. Second, it does not allow suicient appreciation of details on vessel extent, localization, leakage, origin, and diferentiation of the aferent and eferent systems.…”

Section: Paraclinical Evaluation Of Corneal Vascularizationmentioning

confidence: 99%

Corneal Angiogenesis: Etiologies, Complications, and Management

Feizi¹

2017

Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

View full text Add to dashboard Cite

A large subset of corneal pathologies involves the formation of new blood vessels, leading to compromised visual acuity. Additionally, neovascularization of the cornea worsens the prognosis of subsequent penetrating keratoplasty, keeping the patient in a vicious circle of poor prognosis. Ocular angiogenesis results from the upregulation of proangiogenic and downregulation of antiangiogenic factors. There is a tremendous need for developing efective measures to prevent and/or treat corneal neovascularization. Topical steroid medication, cautery, argon and yellow dye laser, and ine needle diathermy have all been advocated with varying degrees of success. The process of corneal neovascularization is primarily mediated by the vascular endothelial growth factor family of proteins, and current therapies are aimed at disrupting the various steps in this pathway. This article aims to review the clinical causes and presentations of corneal neovascularization caused by diferent etiologies. Moreover, this chapter reviews diferent complications caused by corneal neovascularization and summarizes the most relevant treatments available so far.

show abstract

Inhibition of experimental angiogenesis of cornea by somatostatin

Abstract: Our study demonstrated that SST 14 can reduce bFGF-induced corneal angiogenesis. This shows the potential value of somatostatin in the treatment of corneal neovascularization.

Cited by 39 publications

References 24 publications

Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model

Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model

Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model

Corneal Angiogenesis: Etiologies, Complications, and Management

Contact Info

Product

Resources

About